We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Insmed Incorporated

News List

First bronchiectasis patient dosed in Phase III trial to study brensocatib europeanpharmaceuticalreview
December 04, 2020
The first patient with bronchiectasis has been dosed in the Phase III ASPEN study of brensocatib, a reversible inhibitor of dipeptidyl peptidase 1.
EC Grants Authorization for ARIKAYCE Liposomal Nebulizer Dispersion for NTM Lung Infections americanpharmaceuticalreview
November 06, 2020
Insmed Incorporated announced the European Commission (EC) has granted marketing authorization for ARIKAYCE® Liposomal 590 mg Nebulizer Dispersion for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium ...